New combo therapy aims to boost recovery after stroke

NCT ID NCT07162363

Not yet recruiting Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining minimally invasive surgery with a drug called deferoxamine helps people recover better after a brain hemorrhage. The surgery removes the blood clot, while the drug may protect brain cells. About 240 adults with moderate to severe bleeding will be randomly assigned to get the combo or standard care, and their recovery will be tracked for 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: deferoxamine
What this could lead to: If it works, this could lead to a new standard treatment that improves functional recovery and reduces disability after a brain bleed.
What could go wrong: This is an early combined approach; the surgery and drug each carry risks like infection, bleeding, or allergic reactions. Success in this mid-stage trial is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ICH - INTRACEREBRAL HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ICH - INTRACEREBRAL HEMORRHAGE INTRACEREBRAL HEMORRHAGE

Contacts and locations

Locations

University of Illinois Hospital & Health Sciences System (UI Health)

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.